RBC Capital analyst Craig Wong-Pan raised the firm’s price target on ResMed (RMD) to $314 from $311 and keeps an Outperform rating on the shares. The company delivered a strong result with double-digit revenue and earnings growth, the analyst tells investors in a research note. ResMed achieved robust growth across all markets and continued to deliver gross margin improvement and operating leverage, the firm added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: